Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)

Phase 2 Not yet recruiting 35 enrolled Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

NaSingle-groupOpen-labelTreatment

Summary

This is an open label, multicenter, phase II study evaluating the activity and safety of pembrolizumab combined with cisplatin/carboplatin and etoposide as first line treatment in patients with advanced MCC.

Timeline

Start: 2023-11
Primary completion: 2027-12
Completion: 2027-12

Publications

Oldani S, Prinzi N, Morano F, Cingarlini S, Di Giacomo AM, Niger M, Prisciandaro M, Raimondi A, Randon G, Pircher CC, Borghesani M, Valente M, Rostanzo E, Milione M, Sabella G, Cascella T, Ghelardi F, Sciortino C, Gusmaroli E, Nasca V, de Braud F, Pietrantonio F, Pusceddu S. Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma. Future Oncol. 2025 Jul;21(17):2127-2133. doi: 10.1080/14796694.2025.2514402. Epub 2025 Jun 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	—	—
Subject	Cisplatin	Other / unclassified	—	—
Subject	Etoposide	Small molecule	—	—
Subject	Pembrolizumab	Monoclonal antibody	200 mg	—
Subject	Pembrolizumab	Monoclonal antibody	400 mg	—

Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)

Summary

Timeline

Publications

Drugs

Indications